1. Home
  2. APPS vs LBRX Comparison

APPS vs LBRX Comparison

Compare APPS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Turbine Inc.

APPS

Digital Turbine Inc.

HOLD

Current Price

$8.09

Market Cap

974.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$39.94

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPS
LBRX
Founded
N/A
2015
Country
United States
United States
Employees
620
27
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
974.7M
1.0B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
APPS
LBRX
Price
$8.09
$39.94
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.25
$46.60
AVG Volume (30 Days)
2.9M
303.5K
Earning Date
06-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
62.92
N/A
EPS
N/A
N/A
Revenue
$103,569,000.00
N/A
Revenue This Year
$15.60
N/A
Revenue Next Year
$11.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
38.55
N/A
52 Week Low
$2.74
$13.40
52 Week High
$13.60
$41.33

Technical Indicators

Market Signals
Indicator
APPS
LBRX
Relative Strength Index (RSI) 40.88 73.55
Support Level $3.85 $27.40
Resistance Level $8.28 N/A
Average True Range (ATR) 0.67 2.59
MACD -0.20 0.74
Stochastic Oscillator 5.94 92.15

Price Performance

Historical Comparison
APPS
LBRX

About APPS Digital Turbine Inc.

Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: